← All countries · Americas
94.2%
MCV1
2025 · Administrative (country-reported)
98.2%
DTP3
2025 · Administrative (country-reported)
98.2%
IPV complete
2025 · Administrative (country-reported)
98.2%
HepB3
2025 · Administrative (country-reported)
0
Measles cases
2025 reported
0
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 97.8%2025 · Administrative (country-reported) | 97.8% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 100%2025 · Administrative (country-reported) | 100% | D · poor | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| IPV1First dose of inactivated polio vaccine | 98.6%2025 · Administrative (country-reported) | 98.6% | D · poor | |
| IPV completeInactivated polio vaccine, complete primary series | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| MCV1First dose of measles-containing vaccine | 94.2%2025 · Administrative (country-reported) | 94.2% | D · poor | |
| MCV2Second dose of measles-containing vaccine | 86.4%2025 · Administrative (country-reported) | 86.4% | D · poor | |
| RCV1First dose of rubella-containing vaccine | 94.2%2025 · Administrative (country-reported) | 94.2% | D · poor | |
| HepB3Third dose of hepatitis B vaccine | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | 99.5%2025 · Administrative (country-reported) | 99.5% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| PCV1Pneumococcal conjugate vaccine, first dose | 0%2020 · Administrative (country-reported) | 0% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 0%2020 · Administrative (country-reported) | 0% | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | 0%2020 · Administrative (country-reported) | 0% | too few points | D · poor |
| Yellow feverYellow fever vaccine (countries at risk) | 0%2020 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | 0%2020 · Administrative (country-reported) | 0% | too few points | D · poor |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 100%2025 · Administrative (country-reported) | 100% | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | C · weak | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02019 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | D · poor | |
| Typhoid all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (42 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B-M24 | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | Y7-Y11 | Catch-up children | Given to children age 7 to 10 years who missed doses |
| DTWPDTwP (Whole cell) vaccine | 4 | M18 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y3 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y15 | Catch-up children | 1st contact from >=15 years who missed their childhood doses |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M1 | Catch-up children | 1st contact from >=15 years who missed their childhood doses |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M6 | Catch-up children | 1st contact from >=15 years who missed their childhood doses |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | Introduction began 4th quarter of 2019, disrupted by COVID-19 outbreak |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11 | HPV administered to females and males | Quadrivalent vaccine for girls 9+ years, but focus on 11 year old girls up to 26 years old women. The first HPV vaccine was bivalent and it was introduced on February 1st 2019 to girls only. The quadrivalent is being to administered to both male and females. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons age 60 and older |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Y1 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y3 | General/routine | |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | |
| OPVOPV (Oral polio vaccine) | 4 | M18 | General/routine | |
| OPVOPV (Oral polio vaccine) | 5 | Y3 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Catch-up adults | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >=Y15 | Catch-up children | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Catch-up adults | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Catch-up children | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Catch-up adults | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Catch-up children | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y11-Y12 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | >=M9 | Travellers | Only for travelers to endemic countries. Can be administered to travelers as young as 9/12 |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.